These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 11590976)

  • 21. Autistic traits in obsessive-compulsive disorder.
    Bejerot S; Nylander L; Lindström E
    Nord J Psychiatry; 2001; 55(3):169-76. PubMed ID: 11827611
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of a Snoezelen room on the behavior of three autistic clients.
    McKee SA; Harris GT; Rice ME; Silk L
    Res Dev Disabil; 2007; 28(3):304-16. PubMed ID: 16806812
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clozapine maintenance therapy in schizophrenia.
    Gaszner P; Makkos Z
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 May; 28(3):465-9. PubMed ID: 15093952
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cyproheptadine in the treatment of autistic disorder: a double-blind placebo-controlled trial.
    Akhondzadeh S; Erfani S; Mohammadi MR; Tehrani-Doost M; Amini H; Gudarzi SS; Yasamy MT
    J Clin Pharm Ther; 2004 Apr; 29(2):145-50. PubMed ID: 15068403
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Social and communication behaviours in infants and toddlers with autism and pervasive developmental disorder-not otherwise specified.
    Fodstad JC; Matson JL; Hess J; Neal D
    Dev Neurorehabil; 2009 Jun; 12(3):152-7. PubMed ID: 19466623
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Levetiracetam versus placebo in childhood and adolescent autism: a double-blind placebo-controlled study.
    Wasserman S; Iyengar R; Chaplin WF; Watner D; Waldoks SE; Anagnostou E; Soorya L; Hollander E
    Int Clin Psychopharmacol; 2006 Nov; 21(6):363-7. PubMed ID: 17012983
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacological management of agitation and aggression in an adolescent with autism.
    Kratochvil CJ; Findling RL; McDougle CJ; Scahill L; Hamarman S
    J Am Acad Child Adolesc Psychiatry; 2005 Aug; 44(8):829-32. PubMed ID: 16034286
    [No Abstract]   [Full Text] [Related]  

  • 28. Social goals and conflict strategies of individuals with mild to moderate intellectual disabilities who present problems of aggression.
    Pert C; Jahoda A
    J Intellect Disabil Res; 2008 May; 52(Pt 5):393-403. PubMed ID: 18221332
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characteristics of challenging behaviours in adults with autistic disorder, PDD-NOS, and intellectual disability.
    Matson JL; Rivet TT
    J Intellect Dev Disabil; 2008 Dec; 33(4):323-9. PubMed ID: 19039692
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acute effects of baclofen, a gamma-aminobutyric acid-B agonist, on laboratory measures of aggressive and escape responses of adult male parolees with and without a history of conduct disorder.
    Cherek DR; Lane SD; Pietras CJ; Sharon J; Steinberg JL
    Psychopharmacology (Berl); 2002 Nov; 164(2):160-7. PubMed ID: 12404078
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of clozapine on sleep in bipolar and schizoaffective disorders.
    Armitage R; Cole D; Suppes T; Ozcan ME
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Nov; 28(7):1065-70. PubMed ID: 15610918
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Augmentation of clozapine with valproic Acid for clozapine-induced obsessive-compulsive symptoms.
    Zink M; Englisch S; Knopf U; Kuwilsky A; Dressing H
    Pharmacopsychiatry; 2007 Sep; 40(5):202-3. PubMed ID: 17874353
    [No Abstract]   [Full Text] [Related]  

  • 33. Adjunctive treatment with risperidone in clozapine-resistant schizophrenia: a case report and review.
    Lerma-Carrillo I; Molina JD; Cuevas-Durán T; González-Parra S; Blasco-Fontecilla H; Andrade-Rosa C; López-Muñoz F; Alamo C
    Clin Neuropharmacol; 2007; 30(2):114-21. PubMed ID: 17414944
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risperidone: a potential treatment for autism.
    Posey DJ; McDougle CJ
    Curr Opin Investig Drugs; 2002 Aug; 3(8):1212-6. PubMed ID: 12211417
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neuropeptides and social behaviour: effects of oxytocin and vasopressin in humans.
    Heinrichs M; Domes G
    Prog Brain Res; 2008; 170():337-50. PubMed ID: 18655894
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of atypical antipsychotics in the treatment of autistic disorder.
    Stachnik JM; Nunn-Thompson C
    Ann Pharmacother; 2007 Apr; 41(4):626-34. PubMed ID: 17389666
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oral ketamine for the management of combative autistic adult.
    Bachenberg KL
    Anesthesiology; 1998 Aug; 89(2):549-50. PubMed ID: 9710429
    [No Abstract]   [Full Text] [Related]  

  • 38. Negative results with clomipramine.
    Magen J
    J Am Acad Child Adolesc Psychiatry; 1993 Sep; 32(5):1079-80. PubMed ID: 8407757
    [No Abstract]   [Full Text] [Related]  

  • 39. Effect of 5,6-dihydroxytryptamine on social behaviour in mice [proceedings].
    Pöschlová N; Masek K; Krsiak M
    Act Nerv Super (Praha); 1976; 18(3):229-30. PubMed ID: 1007865
    [No Abstract]   [Full Text] [Related]  

  • 40. Use of clonidine for behavioral control in an adult patient with autism.
    Koshes RJ; Rock NL
    Am J Psychiatry; 1994 Nov; 151(11):1714. PubMed ID: 7943466
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.